Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Role of anti-interleukin-2 receptor antibodies in kidney transplantation
Autore:
Cibrik, DM; Kaplan, B; Meier-Kriesche, HU;
Indirizzi:
Univ Michigan, Ann Arbor, MI 48109 USA Univ Michigan Ann Arbor MI USA 48109 iv Michigan, Ann Arbor, MI 48109 USA
Titolo Testata:
BIODRUGS
fascicolo: 10, volume: 15, anno: 2001,
pagine: 655 - 666
SICI:
1173-8804(2001)15:10<655:ROARAI>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
RENAL-ALLOGRAFT RECIPIENTS; ACUTE CELLULAR REJECTION; PREVENT ACUTE REJECTION; MONOCLONAL-ANTIBODY; INTERLEUKIN-2 RECEPTOR; MYCOPHENOLATE-MOFETIL; BASILIXIMAB; DACLIZUMAB; POPULATION; TRIAL;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
41
Recensione:
Indirizzi per estratti:
Indirizzo: Cibrik, DM Univ Michigan, 1414 Catherine ,CFOB B1906, Ann Arbor, MI 48109 USA Univ Michigan 1414 Catherine ,CFOB B1906 Ann Arbor MI USA 48109
Citazione:
D.M. Cibrik et al., "Role of anti-interleukin-2 receptor antibodies in kidney transplantation", BIODRUGS, 15(10), 2001, pp. 655-666

Abstract

From the early 1960s, the mainstay of immunosuppression for kidney transplantation has been corticosteroids. Since then, many new drugs have been developed to maintain the renal allograft. Current maintenance immunosuppression commonly consists of corticosteroids, antiproliferative agents and calcineurin inhibitors (e.g. cyclosporin). More recently, antihuman antibodies, either monoclonal or polyclonal, have been developed to use for induction at the time of transplantation or to treat rejection. With the advances in molecular technology, a new class of antihuman antibodies [the anti-interleukin-2 receptor (IL-2R) antibodies] has emerged that incorporate a murine antigen-binding site on to a human immunoglobulin backbone. Such methodology creates antihuman antibodies with high affinity for the epitope and with prolonged serum antibody half-lives. Interleukin-2 and its receptor are central to lymphocyte activation and are the main targets of calcineurin inhibitors. In addition, the anti-IL-2R antibodies inhibit a key target in immune activation. Daclizumab and basiliximab have been shown to significantly reduce the incidence of acute,rejection in kidney transplantation. Since these anti-IL-2R antibodies are well tolerated and since. calcineurin inhibitors are intrinsically nephrotoxic, anti-IL-2R antibodies have been used in an attempt to avoid cyclosporin aftertransplantation. Data from clinical trials seem to indicate that the addition of an anti-IL-2R antibody is not sufficient to warrant complete withdrawal of calcineurin inhibitors for more than a very short period after transplantation. A more promising role for anti-IL-2R antibodies may be in renaltransplant recipients with delayed graft function (DGF). Recent data on the use of either low-dose calcineurin inhibitors or sirolimus (rapamycin) inconjunction with the anti-IL-2R antibodies for patients with DGF showed noincreased risk of acute rejection. Long-term graft survival with use of these low-dose calcineurin inhibitor protocols has yet to be established.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/09/20 alle ore 00:12:06